Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2019 | AALL0631: lestaurtinib for infant ALL

Patrick Brown • 7 Dec 2019
ASH 2019
Acute Lymphoblastic Leukemia Leukemia Lestaurtinib
AALL0631

Patrick Brown, MD, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD, discusses the results from the AALL0631 study (NCT00557193) of infant ALL patients treated with lestaurtinib at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.

More from Patrick Brown

2:44
Promising results for blinatumomab in younger B-ALL at first relapsed
Patrick Brown • 7 Dec 2019
4:36
Promising results for blinatumomab in younger relapsed B-ALL
Patrick Brown • 10 Dec 2019

Related Videos

1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024
4:19
Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL
Alberto Olaya-Vargas • 15 Apr 2024
3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals